Abstract Library

#2777 Tumor-to-Liver Ratio of Ga-68-DOTATOC PET/CT as a Prognostic Parameter in Metastatic, Well-Differentiated Gastroenteropancreatic-Neuroendocrine Tumor Patients Who Received Lanreotide Therapy

Introduction: Lanreotide is a long-acting somatostatin analogue with proven antitumor effect against metastatic, well-differentiated gastroenteropancreatic-neuroendocrine tumors (GEP-NETs). Ga-68-DOTATOC PET/CT is a sensitive imaging technique for NETs by targeting somatostatin receptors.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author:

Authors: Kim Y, Yoo C, Ryoo B, Ryu J,

Keywords: neuroendocrine tumor, lanreotide, somatostatin receptor, DOTATOC, positron emission tomography, prognosis,

#2292 PFS and OS after Salvage Peptide Receptor Radionuclide Therapy (PRRT) with 177Lu-DOTATATE in Patients with Gastroenteropancreatic or Bronchial Neuroendocrine Tumors (GEP-NETs) – The Rotterdam Cohort

Introduction: PRRT with 177Lu-DOTATATE (LuTate) is effective in patients with metastatic or inoperable GEP-NETs.

Conference: 15th Annual ENETSConcerence (2018)

Presenting Author: van der Zwan W

Authors: Van der Zwan W, Brabander T, Kam B, Teunissen J, Krenning E,

Keywords: Salvage, PRRT, Re-treatment, GEP-NET, Safety, Efficacy, 177Lu-DOTATATE,

#944 Pheochromocytoma and Paraganglioma in Pediatric Age

Introduction: Pheochromocytoma (PHE) and paraganglioma (PGL) are rare tumors of the adrenal medulla and extra-adrenal sympathetic chromaffin tissue. Nearly 30% of them are familiar or associated with genetic syndromes (VHL, MEN2, NF1, SDH mutation, Pacak-Zhuang). Only 20% PHE occur before 20 years of age. Incidence of pediatric PHE is 0.3:1 million.

Conference: 11th Annual ENETSConcerence (2014)

Presenting Author: Bajciova V

Authors: Bajciova V, Kren L, Vicha A,

Keywords: pheochromocytoma, paraganglioma, pediatric age,

#855 Extrapulmonary Small Cell Neuroendocrine Carcinoma of the Colon in an 18-Year-Old Girl

Introduction: Extrapulmonary small cell carcinoma (EPSCC) is a very rare aggressive malignant tumor typical for older age. Prognosis of EPSCC remains very poor, with three years OS 38% and five years OS less than 13%. The median survival for GI localised EPSCC is only five months. Initial extent of disease is the most sensitive prognostic factor.

Conference: 11th Annual ENETSConcerence (2014)

Presenting Author: Bajciova V

Authors: Bajciova V, Kren L, Oltova A,

Keywords: colon EPSCC, young age,

#698 Feasability of a Dosimetry Guided Therapy Planning for Peptide Receptor Radionuclide Therapy with 177Lu-DOTA-Octreotate

Introduction: The efficacy and safety profile of PRRT can theoretically be optimized by planning each individual patient treatment on the absorbed dose to the critical organs and tumor lesions.

Conference: 10th Annual ENETSConcerence (2013)

Presenting Author:

Authors: Krenning E, Erion J, Boesen-de Cock J, Kooij P, Kwekkeboom D,

Keywords: PRRT, dosimetry,